Cannell & Spears LLC Purchases 5,415 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cannell & Spears LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 50.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 16,055 shares of the biopharmaceutical company’s stock after acquiring an additional 5,415 shares during the period. Cannell & Spears LLC’s holdings in Regeneron Pharmaceuticals were worth $11,436,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $26,000. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $28,000. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. Avalon Trust Co purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $36,000. Finally, Crowley Wealth Management Inc. purchased a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $637.36 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $629.02 and a fifty-two week high of $1,211.20. The firm has a market cap of $69.68 billion, a PE ratio of 16.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The business has a 50 day moving average price of $683.88 and a 200-day moving average price of $795.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the prior year, the company posted $11.86 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.55%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Wall Street Analyst Weigh In

REGN has been the topic of a number of recent analyst reports. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. TD Cowen lowered their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Finally, Robert W. Baird reduced their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.